Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/12639
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Beart, P M | en |
dc.contributor.author | O'Shea, R D | en |
dc.contributor.author | Manallack, D T | en |
dc.date.accessioned | 2015-05-16T02:21:55Z | |
dc.date.available | 2015-05-16T02:21:55Z | |
dc.date.issued | 1989-09-01 | en |
dc.identifier.citation | Journal of Neurochemistry; 53(3): 779-88 | en |
dc.identifier.govdoc | 2569504 | en |
dc.identifier.other | PUBMED | en |
dc.identifier.uri | http://ahro.austin.org.au/austinjspui/handle/1/12639 | en |
dc.description.abstract | The regulation of the central sigma-binding site was investigated using both in vitro and in vivo manipulations in conjunction with radioligand binding. The displacement of the binding of R(+)-[3H]3-[3-hydroxyphenyl]-N-(1-propyl)piperidine [R(+)-[3H]3-PPP] to cortical homogenates by a range of drugs was consistent with the site labelled being a sigma-receptor. (+)-SKF 10,047, (-)-SKF 10,047, (+/-)-cyclazocine, phencyclidine, and dexoxadrol displaced R(+)-[3H]3-PPP with pseudo-Hill coefficients of less than 1. Further analysis employing nonlinear curve fitting techniques demonstrated that displacement data for these compounds were described better by a model whereby R(+)-[3H]3-PPP was displaced from two discrete sites; approximately 65% of the total sites were in the high-affinity state. In the presence of 10 mM Mg2+ and 0.3 mM GTP, displacement curves for (+)-SKF 10,047 and (+/-)-cyclazocine were shifted to the right. These findings were due to the shift of some 15% of the high-affinity binding sites to a low-affinity state. Saturation experiments revealed that 0.3 mM GTP acted competitively to decrease the affinity of R(+)-[3H]3-PPP for the sigma sites. The sigma-binding site was thus likely to be linked to a guanine nucleotide regulatory (G) protein. Thus sigma drugs could be subdivided on the basis of their GTP sensitivity and pseudo-Hill coefficients, and by analogy with other receptors R(+)-3-PPP, (+)-SKF 10,047, and (+/-)-cyclazocine, may be putative sigma-agonists. 1,3-Di(2-tolyl)guanidine (DTG), rimcazole, and haloperidol displaced R(+)-[3H]3-PPP with pseudo-Hill coefficients of approximately unity and thus may be sigma-antagonists. Subchronic treatment with rimcazole was characterized by slight sedation and a concomitant up-regulation, with a decrease in the affinity, of sigma-binding sites. The schedule of rimcazole also increased dopamine turnover in the nucleus accumbens; both the concentration of 3,4-dihydroxyphenylacetic acid (DOPAC) and the DOPAC/dopamine ratio were elevated. DTG produced similar alterations to the binding parameters of the sigma-binding site; however, changes were not observed in general behavior or accumbal dopamine turnover. sigma-Receptors are likely to be linked to a G protein and are functionally involved in the CNS. | en |
dc.language.iso | en | en |
dc.subject.other | 3,4-Dihydroxyphenylacetic Acid.metabolism | en |
dc.subject.other | Animals | en |
dc.subject.other | Binding, Competitive | en |
dc.subject.other | Brain.metabolism | en |
dc.subject.other | Carbazoles.pharmacology | en |
dc.subject.other | Cyclazocine.metabolism | en |
dc.subject.other | Dopamine.metabolism | en |
dc.subject.other | Dopamine Agents | en |
dc.subject.other | GTP-Binding Proteins.metabolism | en |
dc.subject.other | Guanidines.pharmacology | en |
dc.subject.other | Guanosine Triphosphate.pharmacology | en |
dc.subject.other | Magnesium.pharmacology | en |
dc.subject.other | Male | en |
dc.subject.other | Phenazocine.analogs & derivatives.pharmacology | en |
dc.subject.other | Rats | en |
dc.subject.other | Rats, Inbred Strains | en |
dc.subject.other | Receptors, Opioid.drug effects.metabolism | en |
dc.subject.other | Receptors, sigma | en |
dc.title | Regulation of sigma-receptors: high- and low-affinity agonist states, GTP shifts, and up-regulation by rimcazole and 1,3-Di(2-tolyl)guanidine. | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | Journal of neurochemistry | en |
dc.identifier.affiliation | University of Melbourne, Clinical Pharmacology and Therapeutics Unit, Austin Hospital, Heidelberg, Victoria. | en |
dc.description.pages | 779-88 | en |
dc.relation.url | https://pubmed.ncbi.nlm.nih.gov/2569504 | en |
dc.type.austin | Journal Article | en |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | No Fulltext | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | none | - |
item.languageiso639-1 | en | - |
item.openairetype | Journal Article | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.